In this case, the patient was treated with a targeted combination chemotherapy regimen containing Pola, which is a novel antibody–drug conjugate (ADC) primarily used for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Here, POLA1 is linked to diffuse large B-cell lymphoma.